Category Archives: Parkinson’s Treatment

SAN DIEGO--(BUSINESS WIRE)-- - ACADIA to initiate second pivotal study in the first half of 2020 - Conference call and webcast to be held today at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. Continue reading →

Parkinson's disease is caused by loss of nerve cells in part of the brain called the substantia nigra, which leads to a reduction in a chemical called dopamine in the brain. Dopamine plays a vital role regulating the movement of the body so a loss of this chemical can cause movement problems. As the condition progresses, the symptoms of Parkinson's disease can get worse and it can become increasingly difficult to carry out everyday activities without help so it is important to recognise the early warning signs to maintain quality of life for as long as possible Continue reading →

Some diseases of the brain are incredibly hard to treat. Parkinsons Disease. Alzheimers Continue reading →

Dog and medical enthusiasts gathered to support and learn more about PADs for Parkinsons. The nonprofit that trains dogs to sniff out Parkinsons Disease held a fundraising and outreach presentation on Nov. 16 at Brickworks Continue reading →

Tiny and traceable man-made crystals, known as quantum dots, may be useful in carrying toxins to select cells in the brain, allowing researchers to better understand Parkinsons neurodegenerative processes by being able to model and visualize them, researchers in Canada report. Their study, Quantum dot conjugated saporin activates microglia and induces selective substantia nigra degeneration, was published in NeuroToxicology Continue reading →

Global Parkinsons Disease Treatments Market 2019 2026 Report gives an overview of the related market involving types, applications and key manufacturers with characteristics, technology and market chain with analysis and recent market trends and development. The report has opinions from industry experts and offers an outline of the past years and the current market situation. Continue reading →

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced today that the U.S. Food and Drug Administration (FDA) has granted the Rare Pediatric Disease designation for sarizotan, the companys product candidate for the treatment of Rett syndrome, a rare neurodevelopmental disorder primarily affecting females, with no approved treatments currently available. Continue reading →

The first thing Gene Freund did after undergoing an incisionless brain procedure intended to still the tremors in his right hand was reach for a flimsy Styrofoam cup on a hospital side table. Continue reading →

According to an internal document seen byThe Guardian,the NHS is facing significant shortages of a number of lifesaving medicines for the treatment of cancer, heart conditions and epilepsy. The document was sent to doctors from the medicine supply team at the Department of Health and Social Care (DHSC), and allegedly listed various drugs that the NHS is facing shortages of. Continue reading →

New research by Fior Markets gives complete guidance which covers the most recent Parkinsons Disease Treatment industry patterns including market development openings, size, share, and development trends. The report specifically focuses on market volume and value at the global level, regional level, and company level. Continue reading →